Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. Coli nitroreductase

International Journal of Cancer

Volumn 86, Issue 6, 2000, Pages 848-854

  Weedon, Sarah J ^a   Green, Nicola K ^a   McNeish, Iain A ^a   Gilligan, Moira G ^a   Mautner, Vivien ^a   Wrighton, Christopher J ^b   Mountain, Andrew ^b   Young, Lawrence S ^a   Kerr, David J ^a   Searle, Peter F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITROREDUCTASE; VIRUS VECTOR;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOMA; CARCINOMATOUS PERITONITIS; ESCHERICHIA COLI; HUMAN; HUMAN CELL; OVARY TUMOR; PRIORITY JOURNAL; SENSITIZATION; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA; CELL LINE; CELL SURVIVAL; CISPLATIN; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; NITROREDUCTASES; PRODRUGS;

EID: 0034660014     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000615)86:6<848::AID-IJC14>3.0.CO;2-B     Document Type: Article

References (21)

1. ANLEZARK, G.M., MELTON, R.G., SHERWOOD, R.F., COLES, B., FRIEDLOS, F. and KNOX, R.J., The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol., 44, 2289-2295 (1992).
2. AUSTIN, E.A. and HUBER, B.E., A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol., 43, 380-387 (1993).
3. BRIDGEWATER, J.A., KNOX, R.J., PITTS, J.D., COLLINS, M.K. and SPRINGER, C.J., The bystander effect of the nitroreductase CB1954 enzyme prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther., 8, 709-717 (1997).
4. BRIDGEWATER, J.A., SPRINGER, C.J., KNOX, R.J., MINTON, N.P., MICHAEL, N.P. and COLLINS, M.K., Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Europ. J. Cancer, 31A, 2362-2370 (1995).
5. CLARK, A.J., IWOBI, M., CUI, W., CROMPTON, M., HAROLD, G., HOBBS, S., KAMALATI, T., KNOX, R., NEIL, C., YULL, F. and GUSTERSON, B., Selective cell ablation in transgenic mice expressing E. coli nitroreductase. Gene Ther., 4, 101-110 (1997).
6. CONNORS, T.A., The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther., 2, 702-709 (1995).
7. DOUGLAS, J.T. and CURIEL, D.T., Targeted adenoviral vectors for cancer gene therapy. Int. J. Oncol., 11, 341-348 (1997).
8. DRABEK, D., GUY, J., CRAIG, R. and GROSVELD, F., The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther., 4, 93-100 (1997).
9. FREI, E., TEICHER, B.A., HOLDEN, S.A., CATHCART, K.N.S. and WANG, Y., Preclinical studies and correlation of the effects of alkylating dose. Cancer Res., 48, 6417-6423 (1988).
10. GILLIGAN, M.G., KNOX, P., WEEDON, S., BARTON, R., KERR, D.J., SEARLE, P. and YOUNG, L.S., Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther., 5, 965-974 (1998).
11. GREEN, N.K. and 12 OTHERS, Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E coli nitroreductase gene. Cancer Gene Ther., 4, 229-238 (1997).
12. HEROD, J.J.O., KERR, D.J. and LUESLEY, D.M., Mechanisms of resistance to platinum chemotherapeutic agents. Contemp. Rev. Obstet. Gynaecol., 7, 25-28 (1995).
13. HUBER, B.E., RICHARDS, C.A. and KRENITSKY, T.A., Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. nat. Acad. Sci. (Wash.), 88, 8039-8043 (1991).
14. KNOX, R.J., FRIEDLOS, F., JARMAN, M. and ROBERTS, J.J., A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol., 37, 4661-4669 (1988).
15. KNOX, R.J., FRIEDLOS, F., MARCHBANK, T. and ROBERTS, J.J., Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol., 42, 1691-1697 (1991).
16. KNOX, R.J., FRIEDLOS, F., SHERWOOD, R.F., MELTON, R.G. and ANLEZARK, G.M., The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol., 44, 2297-2301 (1992).
17. MCNEISH, I.A., GREEN, N.K., GILLIGAN, M.G., FORD, M.J., MAUTNER, V., YOUNG, L.S., KERR, D.J. and SEARLE, P.F., Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther., 5, 1061-1069 (1998).
18. MCNEISH, I.A., SEARLE, P.F., YOUNG, L.S. and KERR, D.J., Gene directed enzyme prodrug therapy for cancer. Adv. Drug Delivery Rev., 26, 173-184 (1997).
19. MULLEN, C.A., KILSTRUP, M. and BLAESE, R.M., Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. nat. Acad. Sci. (Wash.), 89, 33-37 (1992).
20. ROBERTS, J.J., FRIEDLOS, F. and KNOX, R.J., CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an interstrand crosslinking agent in Walker tumour cells. Biochem. biophys. Res. Comm., 140, 1073-1078 (1986).
21. WILKINSON, G.W.G. and AKRIGG, A., Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res., 20, 2233-2239 (1992).